Response by Wetmore et al to Letter Regarding Article, "Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation"

Stroke. 2020 Dec;51(12):e363-e364. doi: 10.1161/STROKEAHA.120.032181. Epub 2020 Nov 23.

Authors

James B Wetmore^{1

2}, Nicholas S Roetker¹, Charles A Herzog^{1

3}

Affiliations

¹ Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN (J.B.W., N.S.R., C.A.H.).
² Division of Nephrology (J.B.W.), Hennepin County Medical Center and Department of Medicine, University of Minnesota, Minneapolis.
³ Division of Cardiology (C.A.H.), Hennepin County Medical Center and Department of Medicine, University of Minnesota, Minneapolis.

PMID: 33226932
DOI: 10.1161/STROKEAHA.120.032181

No abstract available

Publication types

Letter
Comment

MeSH terms

Aged
Anticoagulants / therapeutic use
Atrial Fibrillation* / complications
Atrial Fibrillation* / drug therapy
Atrial Fibrillation* / epidemiology
Factor Xa Inhibitors
Humans
Medicare
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy
Renal Insufficiency, Chronic* / epidemiology
United States / epidemiology
Warfarin / therapeutic use

Substances

Anticoagulants
Factor Xa Inhibitors
Warfarin